獐子島(002069.SZ):積極研究海洋食品在營養健康領域的創新應用
格隆匯3月20日丨獐子島(002069.SZ)在互動平台表示,公司目前主營業務為海蔘、扇貝、鮑魚等海珍品的育苗、養殖、加工及銷售,現有產品線以大眾消費市場為導向,主要產品包括鮮活海珍品(鮑魚、扇貝、海螺、海膽、珍蠔等)、凍鮮調理食品(魚類、貝類、蝦類、蟹類、蛤類等冷凍食材)以及海洋預製菜系列、營養滋補食品(刺蔘、鮑魚、魚子醬精深加工品等)、休閒食品(貝類、蝦類、魚類、蛤類等海洋佐餐零食)等品類,相關產品有較高營養價值。針對兒童、孕婦及嬰兒等特定羣體的營養食品或零食,公司尚未設立獨立產品線,公司會關注消費市場需求變化與政策導向,積極研究海洋食品在營養健康領域的創新應用,並將依規履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.